ASTA Draft Risk Profile Comments

ASTA signed onto industry coalition comments to the Food and Drug Administration (FDA) in February 2021 regarding the FDA's draft guidance titled Voluntary Disclosure of Sesame as an Allergen.

In April 2026, ASTA submitted comments in response to the Food and Drug Administration's (FDA) request for information (RFI) on labeling and cross-contact of gluten in packaged foods, which specifically referenced ingredients that can be declared using collective terms, such as spices. ASTA's comments highlight that no spices inherently contain gluten, note that FDA should take a scientific, risk-based approach to unintended gluten presence, and express support for consistency with existing FDA requirements and harmonization with internal standards for gluten labeling.